Introducing ByonGuard: Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Introducing ByonGuard: Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs

10:00 am - Monday 12th October 2026

Demonstrating rationale to develop conditionally active ADCs to overcome challenges with target-mediated toxicity and improve therapeutic index
Laying out ADC masking mechanism leveraging steric masking nanobody-peptide activated by a variety of proteases in the tumor
Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles

Speakers:

WIM DOKTER

WIM DOKTER

Chief Scientific Officer

Byondis B.V.